- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 559
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more
Clinical trials in Cleveland, Ohio
This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Cleveland
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Cardiac Surgery
- Interventions
- Continuous low-tidal volume ventilation with using FiO2 of 0.21, Continuous low tidal volume ventilation with using FiO2 of 1.0, Apnea During CPB
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 64
- States / cities
- Dothan, Alabama • Glendale, Arizona • Lancaster, California + 57 more
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 581
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more
- Conditions
- Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
- Interventions
- Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy
- Other · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 552
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
- Conditions
- Parkinson Disease, Freezing of Gait
- Interventions
- Multiple Deep Brain Stimulation (DBS) Conditions, Moving Overground in a Virtual Environment (MOVE), Cleveland Clinic Stair Ambulation and Functional Evaluation of Gait (SAFE-Gait)
- Other · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Parkinson's Disease, Deep Brain Stimulation
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
- Interventions
- Cilostazol 100 mg Tablets, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 41 more
- Conditions
- Follicular Lymphoma
- Interventions
- MK-1045, Rituximab, Rituximab biosimilar, Bendamustine, Cyclophosphamide, Vincristine, Prednisone, Prednisolone, Doxorubicin Hydrochloride
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 7
- States / cities
- Duarte, California • Lexington, Kentucky • Hackensack, New Jersey + 4 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 858
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 611
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Tanruprubart
- Drug
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 8 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 18 more